Pages that link to "Q35802755"
Jump to navigation
Jump to search
The following pages link to Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients (Q35802755):
Displaying 50 items.
- Effect of Artemisinins and Amino Alcohol Partner Antimalarials on Mammalian Sarcoendoplasmic Reticulum Calcium Adenosine Triphosphatase Activity (Q22061815) (← links)
- Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria (Q24245437) (← links)
- Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria (Q24246332) (← links)
- Artemether-lumefantrine for treating uncomplicated falciparum malaria (Q24248829) (← links)
- Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria (Q24614989) (← links)
- A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand (Q24814579) (← links)
- Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data (Q26783646) (← links)
- A systematic review of the efficacy of a single dose artemisinin-naphthoquine in treating uncomplicated malaria (Q26786586) (← links)
- Contribution of stochastic partitioning at human embryonic stem cell division to NANOG heterogeneity (Q27333498) (← links)
- Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers (Q28362543) (← links)
- A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria (Q28365926) (← links)
- Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial (Q28469217) (← links)
- A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs (Q28476638) (← links)
- Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial (Q28542921) (← links)
- Measuring Patient Adherence to Malaria Treatment: A Comparison of Results from Self-Report and a Customised Electronic Monitoring Device (Q28546804) (← links)
- Therapeutic Efficacy of Artemether-Lumefantrine (Coartem®) in Treating Uncomplicated P. falciparum Malaria in Metehara, Eastern Ethiopia: Regulatory Clinical Study (Q28551712) (← links)
- HIV-positive nigerian adults harbor significantly higher serum lumefantrine levels than HIV-negative individuals seven days after treatment for Plasmodium falciparum infection (Q30392186) (← links)
- Experience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting (Q30396779) (← links)
- In vitro evidence for auto-induction of artemisinin metabolism in the rat. (Q32030104) (← links)
- Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda (Q33342827) (← links)
- Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda (Q33559051) (← links)
- Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria. (Q33635019) (← links)
- Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy (Q33733033) (← links)
- Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine (Q33738084) (← links)
- Treatment with coartem (artemether-lumefantrine) in Papua New Guinea (Q33749688) (← links)
- Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria (Q33978975) (← links)
- Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo (Q34057403) (← links)
- Artemether-lumefantrine: an option for malaria (Q34267667) (← links)
- Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania (Q34290067) (← links)
- Pharmacokinetic interactions of antimalarial agents (Q34296740) (← links)
- Emerging artemisinin resistance in the border areas of Thailand (Q34343530) (← links)
- How can we do pharmacokinetic studies in the tropics? (Q34387231) (← links)
- Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial (Q34413590) (← links)
- Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children (Q34562333) (← links)
- Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study (Q34728230) (← links)
- Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. (Q34737444) (← links)
- Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola (Q34922694) (← links)
- Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges (Q34953705) (← links)
- Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda (Q34983307) (← links)
- Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review (Q35029488) (← links)
- Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model (Q35107675) (← links)
- Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria (Q35112348) (← links)
- In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia (Q35186075) (← links)
- The effect of mobile phone text-message reminders on Kenyan health workers' adherence to malaria treatment guidelines: a cluster randomised trial (Q35186742) (← links)
- Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria (Q35191375) (← links)
- Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study (Q35218484) (← links)
- Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination (Q35224221) (← links)
- Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications (Q35286119) (← links)
- Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria (Q35363704) (← links)
- The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment (Q35583982) (← links)